huntington's

Selisistat (EX-527) is a potent and specific inhibitor of the deacetylase SIRT1 (IC50 = 38 nM) and can be utilized in the study of neurological disorders such as Huntington's chorea.

Idebenone (CV-2619) is a synthetic analogue of ubiquinone (Coenzyme Q10), a vital cell antioxidant and essential component of the Electron Transport Chain (ETC).

NKL 22 (Histone Deacetylase Inhibitor IV) is an effective Histone Deacetylase Inhibitor.

BN-82451 2HCl is a dual inhibitor of COX-1 and COX-2 and can be used to study Huntington's chorea and Parkinson's disease.

HTT-D3 is an orally active, highly efficient Huntington splicing modulator. It induces HTT mRNA degradation, reduces HTT protein levels, and inhibits P-glycoprotein (P-gp) efflux. This compound can be used in Huntington's disease research.

Dalzanemdor (SAGE-718) is a selective, orally active NMDA receptor (N-methyl-D-aspartate receptor) modulator. By modulating NMDA receptor function, Dalzanemdor enhances glutamatergic neurotransmission, thereby improving neural network activity. Dalzanemdor is being investigated for use in the treatment of Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease.

Rosolutamide (ALZ-003) is a curcumin analog, an orally active Nrf1 and Nrf2 activator.Rosolutamide modulates oxidative homeostasis, improves mitochondrial function and promotes autophagy, reduces mutant protein aggregation, and decreases intracellular/mitochondrial reactive oxygen species (ROS) levels.Rosolutamide has been used in the study of neurodegeneration such as spinal cerebellar ataxia and Huntington disease. neurodegenerative diseases such as Huntington's disease. Regulates oxidative homeostasis.

Tidembersat is a small molecule compound used to treat and/or prevent degenerative diseases such as Huntington's chorea, schizophrenia, neurological.

Tetrabenazine (Ro 1-9569) is a former antipsychotic drug used to treat various movement disorders. It inhibits neurotransmitter uptake into adrenergic storage vesicles and serves as a high-affinity label for the vesicle transport system.

Cystamine (2,2'-Disulfanediyldiethanamine) is an inhibitor of transglutaminase and inhibits caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used in studies about Huntington's diseases.

Meclizine, also known as Meclozine, is a piperazine class H1 antagonist with antihistamine properties that inhibits the interaction of histamine at H1 receptors reversibly. It serves as an effective anti-motion sickness agent, able to cross the blood-brain barrier. Additionally, Meclizine acts as an agonist ligand for the mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR, making it useful in research on polyQ toxicity disorders, including Huntington's disease.

Dantrolene is a postsynaptic muscle relaxant by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors.

Votoplam HCl (PTC-518 HCl) is the hydrochloride form of Votoplam.Votoplam is a systemically acting gene splicing regulator that down-regulates the levels of huntingtin protein, which is primarily used to inhibit Huntington's disease (HD).

CHDI 00484077 is a highly selective, central nervous system (CNS) permeable Class IIa HDAC inhibitor with inhibitory effects on HDAC4, HDAC5, HDAC7, and HDAC9, which improves neuronal function, and can be used to study Huntington's disease.

Tetrabenazine Metabolite ((-)-β-HTBZ), a vesicles monoamine transporter 2 (VMAT2) inhibitor, is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite has a high affinity for VMAT2 with a Ki of 13.4 nM. Tetrabenazine Metabolite is often used to study chorea associated with Huntington's disease and other hyperactivity disorders.

B2 (Linazolamide intermediate B impurity 2) promotes inclusion formation in cellular models of Huntington's disease and Parkinson's disease

NCT-504, a selective allosteric inhibitor of PIP4Kγ, exhibits an IC50 value of 15.8 μM. It holds promise for the investigation of Huntington's disease.

1-phenyl-3,4-dihydroisochinoline (3,4-Dihydro-1-phenylisoquinoline) is a structural analog of the neurotransmitter dopamine that interacts with dopamine receptors in the central nervous system. It has been studied as a potential therapeutic agent for the treatment of neurological disorders such as Parkinson's disease, Alzheimer's disease and Huntington's chorea.

IIQLPEIVVV TFA serves as a specific inhibitor targeting the Drp1-Mff interaction. This compound discriminates between physiological and pathological fission, hindering physiological fission which leads to mitochondrial dysfunction. IIQLPEIVVV TFA is also utilized in research related to Huntington's disease.

(2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. It suppresses the vesicular transport of monoamine neurotransmitters, such as dopamine and serotonin, leading to reduced release into the synaptic cleft. This compound holds potential for research in Huntington's disease and other hyperkinetic movement disorders.

Pyrazolo[1,5-a]pyrimidine 4h is a morpholine derivative that is a selective antagonist of the adenosine A2A receptor. It has been shown to be neuroprotective in animal models of Parkinson's disease and Huntington's chorea.

Chloroguanabenz (acetate) is an antiprion agent derived from guanabenz, an α2-adrenergic receptor agonist. It inhibits prion formation in vitro in both yeast and mammalian models. Additionally, Chloroguanabenz (acetate) reduces levels of the truncated huntingtin protein derivative Htt48 in HEK293T cells and is used for studying Huntington's disease.

RNA splicing modulator-4 (Compound A) is an orally active, brain-penetrant, and selective modulator of RNA splicing. It regulates alternative splicing events to control the inclusion or exclusion of specific exons in precursor mRNA (pre-mRNA), thereby altering the coding sequence and function of mature mRNA. RNA splicing modulator-4 is promising for research in neurodegenerative diseases (such as Huntington's disease) and cancer.

SC 51089 is a selective prostaglandin receptor PGE2 antagonist with selectivity for prostaglandin receptor subtypes and antinociceptive activity that improves motor deficits and rescues memory decline in the Huntington's disease R6/1 mouse model .